Role of 'Pentoxifylline and or IgM Enriched Intravenous Immunoglobulin in the Treatment of Neonatal Sepsis'
Sepsis of the Newborn
About this trial
This is an interventional treatment trial for Sepsis of the Newborn focused on measuring neonatal sepsis, pentoxyfilline, pentaglobin, biomarker, To reduce mortality in neonatal sepsis
Eligibility Criteria
Inclusion Criteria::
- All infants thought/diagnosed to have late or early onset sepsis.
Exclusion Criteria:
- Pentoxifylline or Pentaglobin has already been given
- Pentoxifylline or Pentaglobin is thought to be needed or contra-indicated
- Major congenital anomaly
- Intraventricular hemorrhage (Grade 3 veya 4)
- Congenital infections
- Inborn errors of metabolism
Sites / Locations
- Zekai Tahir Burak
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Placebo Comparator
Active Comparator
Active Comparator
Active Comparator
Placebo group
Pentoxifylline group
Pentaglobin group
Pentoxifylline plus Pentaglobin group
Receiving standard treatment plus placebo (5 mls/Kg of normal saline intravenously given over 4 hours).
Standard treatment plus 6 mg/Kg of Pentoxifylline intravenously (given over 4 hours) daily for three days.
Standard treatment plus 250 mg/Kg of Pentaglobin intravenously (given over 4 hours) daily for three days
Standard treatment plus 6 mg/Kg of Pentoxifylline plus 250 mg/Kg of Pentaglobin intravenously (given over 4 hours) daily for three days.